• Wellness
• Safety and quality
• Telehealth
• FDA

"For research use only": how FDA and the FTC read peptide marketing

By Peptide Policy Watch editorial team · Published October 26, 2026

You've probably seen the setup. A clean product page, a lab-coat photo, a line in small print saying the product is "for research use only." Then, a little further down, a summary of studies suggesting it could help with weight, recovery or sleep. Which part counts, the small print or the pitch?

For federal regulators the answer is mostly the pitch. FDA warning letters and FTC guidance both look at the whole message, not just the disclaimer.

Facts are as of October 26, 2026. Sources, with retrieval dates, are at the bottom.

The disclaimer doesn't decide what a product is

Under federal drug law, what makes something a drug is its intended use: diagnosing, treating or preventing disease, or changing how the body works. FDA judges that intent from evidence, including the seller's own website. [V]

In a March 31, 2026 warning letter to one peptide website, FDA noted the labels said "Research Use Only" and "not intended for human consumption." The agency still concluded that evidence from the website showed the products were meant as drugs for human use. [V] A second letter the same day made the same point about labels reading "in vitroDone in a dish or test tube, using cells or tissue outside a living body. research and educational purposes only." There, FDA also cited "cheat sheets" shared through the company's online community. [V]

FDA's GLP-1 page says the same thing at a larger scale. It has warned firms that sold semaglutide, tirzepatide, retatrutide and related drugs labeled "for research purposes" or "not for human consumption" directly to consumers, with use directions. [V]

Lab studies as sales copy

Here's a quieter pattern. In an August 24, 2026 letter, FDA quoted a company's product pages summarizing laboratory studies, with phrases like "suggests that semaglutide could have potential benefits." [V] FDA treated those summaries as part of the evidence of intended use, and called the products unapproved new drugs. [V]

The FTC comes at this from the advertising side. Its Health Products Compliance Guidance says health claims need competent and reliable scientific evidence, which usually means good-quality human trials. It says animal and test-tube studies generally can't carry that weight on their own. [V]

• 3FDA warning letters to peptide websites we read for this piece, dated March 31 and August 24, 2026 [V]
• ~100cease-and-desist letters FDA said it was sending in its September 2025 crackdown on misleading drug ads [V]

Red flags, in the regulators' own terms

None of these proves a product is unsafe. Each is something FDA or the FTC has called out.

1. A "research only" label on a product sold to the public with use directions. FDA has called that labeling false. [V]
2. Lab or animal results presented as benefits for you. The FTC says that kind of evidence usually isn't enough for a health claim. [V]
3. Testimonials standing in for evidence. The FTC says personal stories don't substantiate a health claim. [V]
4. Soft words doing heavy lifting. "May," "helps," "promising" and "preliminary" don't fix an unsupported claim, per the FTC. [V]
5. Science costume. Lab coats, medical symbols or a "research center" name can imply proof, and the FTC says fine print doesn't cancel that impression. [V]
6. "FDA approved" or "FDA registered" used loosely. The FTC guidance warns against misstating a product's FDA status. [V]
7. Undisclosed paid promotion. The FTC expects material connections with endorsers to be disclosed. FDA's 2025 crackdown announcement also pointed to undisclosed paid influencer promotion as part of the problem. [V]

FDA keeps a separate telehealth list too. It warns about sellers who call a compounded drug identical to an approved one, who price far below what seems plausible, or who skip a licensed doctor's screening before a prescription. [V]

What people get wrong

One more limit worth knowing: the FTC says its guidance doesn't have the force of law by itself. The legal duty comes from the FTC Act; the guidance explains how the agency applies it. [V]

Why it matters

Peptide marketing often borrows the look of science. Knowing how regulators read that look helps you sort a product page into what it really is: a claim, the evidence behind it, and the label that's meant to keep it out of trouble. The approved vs. wellness peptides comparison lays out what an approved label gives you that a product page can't.

What to watch next

FDA posts warning letters on a rolling basis, and we check the list each night for peptide and GLP-1 cases. The FTC's own case against a telehealth company is covered in our telehealth explainer. For the GLP-1 side of this, see semaglutide: approved, compounded or "research".

Sources (all retrieved October 26, 2026)

1. FDA warning letter, MARCS-CMS 721806, March 31, 2026 (company not named here) [V] — https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026
2. FDA warning letter, MARCS-CMS 721600, March 31, 2026 [V] — https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mile-high-compounds-llc-721600-03312026
3. FDA warning letter, MARCS-CMS 735063, August 24, 2026 [V] — https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026
4. FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss," content current as of 10/01/2026 [V] — https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
5. FTC, "Health Products Compliance Guidance" [V] — https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance
6. FDA, "FDA Launches Crackdown on Deceptive Drug Advertising," September 9, 2025 [V] — https://www.fda.gov/news-events/press-announcements/fda-launches-crackdown-deceptive-drug-advertising

Spot a mistake? See how we source and our corrections policy.